SCENTMATIC
8.4.2024 11:32:26 CEST | Business Wire | Press release
SCENTMATIC Inc (CEO: Toshiharu Kurisu, Head office: Tokyo, Japan), which proposes new customer experiences through the digitization of fragrance, announced that their AI service that verbalizes fragrance KAORIUM has been selected as “Retracing innovation and ideas that defined the lifestyle trends of 2023” by STIRworld.com, a leading global digital magazine in the fields of design, architecture, and arts.
* KAORIUM is a registered trademark of SCENTMATIC Inc.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328876250/en/
What's KAORIUM? Read scents, smell words; A journey of fragrance discovery that ignites the olfactory imagination. Finding a perfume is a challenge. Fragrances are hard to grasp, and expressing our preferences can be tough. KAORIUM by SCENTMATIC is an entirely novel approach to fragrance exploration that decodes the enigmatic world of scents and helps people discover new fragrances intuitively through language. Harnessing state-of-the-art technology, our mission is to deliver olfactory moments of delight. When a scent is placed on the coaster, the impression of the scent is visualized in words. By expressing sensory perceptions through language, scents that were once difficult to discern become more clearly perceivable. (Graphic: Business Wire)
STIRworld.com Article page (Published 17 December 2023)
“Retracing innovation and ideas that defined the lifestyle trends of 2023”
https://www.stirworld.com/see-features-retracing-innovation-and-ideas-that-defined-the-lifestyle-trends-of-2023
The article introduces KAORIUM as one of the lifestyle trends that will have a major impact on the global design structure in 2023. The article describes KAORIUM’s process of scent, language, and artificial intelligence uniting to refine the user's scent preferences as “an immersive experience”. KAORIUM was highly evaluated as a lifestyle trend for 2023, defining a new retail experience that cannot be found in traditional perfume selling counters.
About KAORIUM
https://www.youtube.com/embed/0fpDr3zgjeM?feature=oembed
The article was also featured on the Instagram account of STIRworld.com.
STIRworld.com Instagram reel video (Posted on 20 December 2023)
https://www.instagram.com/reel/C1CqKsNywAD/?igsh=cXJxczUzanhxa2to
KAORIUM was in the spotlight when we exhibited this AI system that mutually converts scents and words at the London Design Festival 2023, one of the world's leading design events, held in London, UK, for eight days from 16 to 24 September 2023.
STIRworld.com Article page (Published on 19 September 2023)
https://www.stirworld.com/see-lifestyle-scentmatics-kaorium-at-ldf-2023-explores-language-and-emotion-in-fragrance-selection
In the interview with STIR, Kurisu, Managing Director of SCENTMATIC, introduced the innovations brought by KAORIUM to the Japanese retail industry, as well as its future potential and social impact.
GET IN TOUCH
https://scentmatic.co.jp/contact-en
[SCENTMATIC, Inc.]
SCENTMATIC was established in 2019 as a co-creation fragrance business design group that can add "emotional experience value" to everything using an AI system that verbalizes fragrance. Focusing on the most unknown area of the five senses “smell”, we have developed KAORIUM, an AI tool that verbalizes fragrance. KAORIUM is expected to help businesses to utilize fragrance in a variety of ways. SCENTMATIC is working on the 'digitalization of the sense of smell'. It will revolutionize business in all industries by evolving people's senses through the 'experience of smell' using fragrance and words.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328876250/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom